The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | POET: the predictive and prognostic value of PD-L1 expression in NSCLC
Lorenzo Belluomini, MD, PhD, University of Verona, Verona, Italy, discusses the background behind the POET study whereby the impact of PD-L1 expression on patient outcome was evaluated in cases of non-small cell lung cancer (NSCLC). Dr Belluomini continues by commenting on EGFR tyrosine kinase inhibitor (TKI) resistance and how PDL1 expression may also be able to detect resistance to TKI’s such as osimertinib. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
